The Fellow on Call: The Heme/Onc Podcast Episode 107: Colorectal Cancer Series, Pt. 9 - Metastatic Colorectal Cancer (Part 1)
Jul 10, 2024
Dive into the complexities of metastatic colorectal cancer treatment options! Discover the significance of personalized approaches, including the roles of Bevacizumab and EGFR inhibitors. Learn why mutational analysis and tumor sidedness are crucial in managing this disease. The discussion features a compelling case study that highlights advancements in chemotherapy regimens and patient-centered care. Expect a mix of serious insights and light-hearted moments, like a humorous cowboy boot anecdote!
AI Snips
Chapters
Transcript
Episode notes
Importance of Molecular Profiling
- Molecular profiling including MSI status, HER2, BRAF, and RAS mutations critically guides metastatic colorectal cancer treatment.
- Tumor sidedness (right vs left colon) also impacts treatment decisions and prognosis.
Folfox vs Folfiri Equivalence
- Historically, Folfox and Folfiri chemotherapy regimens showed equivalent effectiveness for metastatic colorectal cancer.
- Choice between regimens depends largely on patient-specific toxicity profiles and preferences.
Optimize Oxaliplatin Use
- Use an intermittent oxaliplatin approach followed by 5-FU maintenance to reduce neuropathy while maintaining efficacy.
- Retreatment with oxaliplatin upon progression after treatment breaks is reasonable.